Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Seven and Eight Biopharmaceuticals to combine BDB001 with Roche’s Tecentriq

Executive Summary

Seven and Eight Biopharmaceuticals Inc. and Roche agreed to trial a combination of the former’s BDB001 and latter’s Tecentriq (atezolizumab) in solid tumors.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Trial Collaborations
    • R&D (No Licensing)

Related Companies

UsernamePublicRestriction

Register